Novel three-dimensional biochip pulmonary sarcoidosis model

PLoS One. 2021 Feb 4;16(2):e0245805. doi: 10.1371/journal.pone.0245805. eCollection 2021.

Abstract

Sarcoidosis is a multi-system disorder of granulomatous inflammation which most commonly affects the lungs. Its etiology and pathogenesis are not well defined in part due to the lack of reliable modeling. Here, we present the development of an in vitro three-dimensional lung-on-chip biochip designed to mimic granuloma formation. A lung on chip fluidic macrodevice was developed and added to our previously developed a lung-on-membrane model (LOMM). Granulomas were cultured from blood samples of patients with sarcoidosis and then inserted in the air-lung-interface of the microchip to create a three-dimensional biochip pulmonary sarcoidosis model (3D BSGM). Cytokines were measured after 48 hours. ELISA testing was performed to measure cytokine response difference between LOMM with 3D BSGM. There were statistically significant differences in IL-1ß (P = 0.001953), IL-6 (P = 0.001953), GM-CSF (P = 0.001953), and INF-γ expressions (P = 0.09375) between two groups. The current model represents the first 3D biochip sarcoidosis model created by adding a microfluidics system to a dual-chambered lung on membrane model and introducing developed sarcoid-granuloma to its air-lung-interface.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Biomimetics / instrumentation*
  • Cytokines / metabolism
  • Humans
  • Lab-On-A-Chip Devices*
  • Leukocytes, Mononuclear / metabolism
  • Sarcoidosis, Pulmonary / pathology*

Substances

  • Cytokines

Grants and funding

This work was supported in part by a Health Resources and Services Administration contract awarded to MM (234–2005–37011C), and Mallinckrodt Pharmaceuticals for research grant support awarded to MM (Grant No. 5043). Genix-Engineering provided support for this study in the form of a salary for BE. The specific roles of this author are articulated in the ‘author contributions’ section. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.